Renaissance Technologies’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$51.6M Buy
66,802
+57,720
+636% +$44.2M 0.08% 316
2025
Q4
$7.01M Sell
9,082
-266,080
-97% -$181M 0.01% 1107
2025
Q3
$155M Buy
275,162
+230,100
+511% +$130M 0.2% 92
2025
Q2
$23.7M Sell
45,062
-33,839
-43% -$18.9M 0.03% 631
2025
Q1
$50M Sell
78,901
-168,842
-68% -$116M 0.08% 320
2024
Q4
$176M Buy
247,743
+36,320
+17% +$30.5M 0.26% 62
2024
Q3
$222M Buy
211,423
+26,261
+14% +$29.2M 0.33% 46
2024
Q2
$195M Buy
185,162
+19,800
+12% +$19.2M 0.33% 48
2024
Q1
$159M Sell
165,362
-77,700
-32% -$73.9M 0.25% 74
2023
Q4
$213M Buy
243,062
+81,000
+50% +$66.7M 0.33% 51
2023
Q3
$133M Buy
162,062
+73,862
+84% +$58M 0.23% 86
2023
Q2
$63.4M Sell
88,200
-26,700
-23% -$20.6M 0.09% 247
2023
Q1
$94.4M Sell
114,900
-76,541
-40% -$57.7M 0.13% 192
2022
Q4
$138M Sell
191,441
-16,959
-8% -$12.5M 0.19% 110
2022
Q3
$144M Sell
208,400
-374,662
-64% -$236M 0.2% 108
2022
Q2
$345M Buy
583,062
+303,200
+108% +$197M 0.41% 43
2022
Q1
$195M Sell
279,862
-3,100
-1% -$1.96M 0.23% 76
2021
Q4
$179M Buy
282,962
+181,700
+179% +$112M 0.22% 83
2021
Q3
$61.3M Buy
+101,262
New +$62.9M 0.08% 257
2021
Q2
Sell
-65,152
Closed -$30.8M 3719
2021
Q1
$30.8M Sell
65,152
-839,800
-93% -$409M 0.04% 550
2020
Q4
$437M Sell
904,952
-167,410
-16% -$90.4M 0.47% 37
2020
Q3
$600M Buy
1,072,362
+182,262
+20% +$111M 0.6% 24
2020
Q2
$555M Buy
890,100
+402,738
+83% +$229M 0.48% 34
2020
Q1
$238M Buy
487,362
+198,962
+69% +$82.1M 0.23% 99
2019
Q4
$108M Sell
288,400
-110,418
-28% -$37.1M 0.08% 259
2019
Q3
$111M Buy
398,818
+60,856
+18% +$18M 0.09% 248
2019
Q2
$106M Buy
337,962
+129,700
+62% +$43.2M 0.09% 249
2019
Q1
$85.5M Sell
208,262
-141,600
-40% -$58.3M 0.08% 303
2018
Q4
$131M Buy
349,862
+81,800
+31% +$29.9M 0.14% 151
2018
Q3
$108M Sell
268,062
-213,400
-44% -$81.2M 0.11% 200
2018
Q2
$166M Sell
481,462
-1,008
-0.2% -$315K 0.18% 111
2018
Q1
$166M Sell
482,470
-97,092
-17% -$33.8M 0.18% 103
2017
Q4
$218M Buy
579,562
+485,600
+517% +$197M 0.24% 64
2017
Q3
$42M Buy
+93,962
New +$44.7M 0.05% 501
2017
Q2
Sell
-232,076
Closed -$89.9M 3330
2017
Q1
$89.9M Sell
232,076
-18,484
-7% -$6.85M 0.13% 179
2016
Q4
$92M Buy
+250,560
New +$95.3M 0.15% 136
2016
Q3
Sell
-210,762
Closed -$73.6M 3466
2016
Q2
$73.6M Sell
210,762
-6,200
-3% -$2.39M 0.14% 135
2016
Q1
$78.2M Buy
216,962
+109,700
+102% +$45.2M 0.15% 122
2015
Q4
$58.2M Buy
+107,262
New +$58.1M 0.13% 180
2015
Q2
Sell
-167,488
Closed -$75.6M 3344
2015
Q1
$75.6M Buy
+167,488
New +$71M 0.16% 116
2014
Q4
Sell
-26,562
Closed -$9.58M 3092
2014
Q3
$9.58M Buy
26,562
+23,700
+828% +$7.94M 0.03% 777
2014
Q2
$808K Buy
+2,862
New +$848K ﹤0.01% 2136
2014
Q1
Sell
-70,062
Closed -$19.3M 2980
2013
Q4
$19.3M Sell
70,062
-179,459
-72% -$51.6M 0.05% 481
2013
Q3
$78.1M Buy
249,521
+14,759
+6% +$3.88M 0.19% 99
2013
Q2
$52.8M Buy
+234,762
New +$54.7M 0.14% 160

Other funds holding REGN

Renaissance Technologies's REGN Position: Q1 2026 in Review

Renaissance Technologies increased its Regeneron Pharmaceuticals (REGN) stake by 636% in Q1 2026, buying an estimated $44.2M and bringing the position to 66,802 shares worth $51.6M. The position accounts for 0.08% of the portfolio, ranked #316.

Renaissance Technologies first reported a position in REGN in Q2 2013 and has held it in 45 quarters since. The position peaked at $600M in Q3 2020. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Renaissance Technologies held 66,802 shares of Regeneron Pharmaceuticals worth $51.6M as of Q1 2026.
  • Renaissance Technologies bought 57,720 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $44.2M.
  • Regeneron Pharmaceuticals made up 0.08% of Renaissance Technologies's portfolio in Q1 2026, its #316 holding.
  • Renaissance Technologies first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
  • Renaissance Technologies's Regeneron Pharmaceuticals position peaked at $600M in Q3 2020.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.